Bridge Bank Extends Venture Term Loan to Deep Lens, Inc.

Costa Mesa, Calif.

Bridge Bank today announced it has extended a venture term loan to Deep Lens, a Columbus, Ohio-based software company focused on accelerating clinical trial recruitment for the best-suited cancer patients to compress study timelines and bring game-changing therapies to market sooner. The company is venture-backed by Northpond Ventures, Sierra Ventures, Rev1 Ventures, and Tamarind Hill.

“We view this additional financing as a vote of confidence for our business strategy as we continue to grow and expand,” said Simon Arkell, president & co-founder of Deep Lens. “Success requires teamwork and we’re delighted to have a business partner like Bridge Bank. The Bridge team really took the time to understand our business proposition.”

“Deep Lens has developed a highly disruptive solution for rapid patient identification in clinical trials,” said Mark Breneman, senior vice president in Bridge Bank’s Technology Banking Group. “We’re very pleased to be working with the Deep Lens team and look forward to supporting their continued growth as they deploy a solution that will truly save lives.”